Holen Sie sich die Stockscreener-App
67.36
1.71%
-1.17
Handel nachbörslich:
67.36
Schlusskurs vom Vortag:
$68.53
Offen:
$68.53
24-Stunden-Volumen:
1.41M
Relative Volume:
0.66
Marktkapitalisierung:
$13.04B
Einnahmen:
$3.29B
Nettoeinkommen (Verlust:
$268.74M
KGV:
49.15
EPS:
1.3704
Netto-Cashflow:
$759.12M
1W Leistung:
+5.56%
1M Leistung:
+14.87%
6M Leistung:
+12.51%
1J Leistung:
+16.14%
1-Tages-Spanne:
$67.12
$68.53
1-Wochen-Bereich:
$63.37
$70.98
52-Wochen-Spanne:
$49.26
$70.98
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
67.36 | 13.60B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Fortgesetzt | Morgan Stanley | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration - simplywall.st
Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth? - Sahm
Summit Global Investments Buys New Stake in BioMarin Pharmaceutical Inc. $BMRN - marketbeat.com
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BMRN vs. ILMN: Which Stock Is the Better Value Option? - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Yahoo Finance
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth - MarketBeat
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High? - Yahoo Finance
BMRN: Strong Q2 growth, Amicus integration, and pipeline expansion position for sustained revenue gains - TradingView
Transcript : BioMarin Pharmaceutical Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-12-2026 08 - marketscreener.com
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Janus Henderson Multi-Sector Income Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD By Investing.com - Investing.com Nigeria
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week High on Analyst Upgrade - marketbeat.com
Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD - Investing.com
BioMarin presentation to stream live from Boston on Aug. 12 - Stock Titan
BMRN Maintained by Canaccord Genuity -- Price Target Raised to $114 - GuruFocus
Canaccord raises BioMarin stock price target on revenue growth By Investing.com - Investing.com Australia
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $114.00 at Canaccord Genuity Group - marketbeat.com
BioMarin scraps BMN 401, ending its $270 million Inozyme bet - The Pharma Letter
Canaccord raises BioMarin stock price target on revenue growth - Investing.com India
BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication - BioSpace
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unveiling a 40% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
BioMarin Pharmaceutical Inc. (BMRN) options chain - Yahoo Finance Australia
Pacer Advisors Inc. Sells 913,713 Shares of BioMarin Pharmaceutical Inc. $BMRN - marketbeat.com
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin (BMRN) Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum - Sahm
BioMarin Pharmaceutical Inc. (BMRN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Assenagon Asset Management S.A. - marketbeat.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded by Wall Street Zen to Buy Rating - marketbeat.com
BioMarin Earnings: Voxzogo Resilience and Amicus Strength Support Positive Outlook - Morningstar
Oppenheimer raises BioMarin stock price target on strong quarter By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside - TradingView
Biomarin Pharmaceutical Inc (BM8.SG) stock price, news, quote and history - Yahoo Finance UK
Morgan Stanley Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
BioMarin bins rare disease asset from Inozyme acquisition - FirstWord PHARMA
BioMarin Pharmaceutical Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BMRN) 2026-08-07 - Seeking Alpha
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised - Yahoo Finance
BioMarin Lifts 2026 Outlook on Strong Voxzogo Sales, Wedbush Says - Yahoo Finance
HC Wainwright Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Oppenheimer Adjusts PT on BioMarin Pharmaceutical to $97 From $95, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises BioMarin stock price target on strong quarter - Investing.com
Earnings call transcript: BioMarin Q2 2026 beats forecasts, lifts outlook By Investing.com - Investing.com Nigeria
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results - MarketBeat
BioMarin (BMRN) Stock May Be Above Fair Value After ReNU Therapy Deal - Yahoo Finance
BioMarin Pharmaceutical Inc (BMRN) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance
Earnings call transcript: BioMarin Q2 2026 beats forecasts, lifts outlook - Investing.com
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):